

APPENDIX B
Pending Claims

1. A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting a lipid specific antibody response with an immunologically effective amount of a composition comprising a phosphatidylserine/polypeptide conjugate.
2. The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
3. The method of claim 1, wherein said cancer cell is comprised within an animal.
4. The method of claim 3, wherein said animal is a human.
5. The method of claim 1, wherein said composition further comprises a pharmaceutical excipient.
6. The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
7. The method of claim 1, wherein said lipid specific antibody response is elicited with phosphatidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β_2 -glycoprotein I.
8. The method of claim 7, wherein said polypeptide is β_2 -glycoprotein I.
12. A method of generating a lipid specific antibody response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition.

29. The method of claim 3, wherein said animal has cancer.

30. The method of claim 29, wherein said animal has a tumor.

31. The method of claim 4, wherein said human has cancer.

32. The method of claim 31, wherein said human has a tumor.

33. The method of claim 12, wherein said animal comprises a cancer cell.

34. The method of claim 33, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.

35. The method of claim 12, wherein said animal has cancer.

36. The method of claim 12, wherein said animal has a tumor.

37. The method of claim 12, wherein said animal is a human.

38. The method of claim 37, wherein said human has cancer.

39. The method of claim 37, wherein said human has a tumor.

40. The method of claim 12, wherein said animal is a mouse.

41. The method of claim 12, wherein said animal is a rat, a hamster, a guinea pig or a goat.

42. The method of claim 12, wherein said composition is administered to said animal topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.

43. The method of claim 12, wherein said lipid specific antibody response is elicited with a phosphotidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β 2-glycoprotein I.

44. The method of claim 43, wherein said polypeptide is β 2-glycoprotein I.